Chimeric Therapeutics halted its phase I/II study of CHM-2101, an autologous cadherin-17-targeted CAR T for gastrointestinal cancers, after a second patient at the highest dose level experienced dose-limiting toxicities. The company said it will stop development of CHM-2101 in its current form. Chimeric also announced a strategic pivot toward an early-stage in vivo CAR program aimed at the same antigen, reflecting an attempt to redesign the therapeutic context to improve tolerability or operational risk. The decision underscores the narrow tolerability windows that often define solid-tumor CAR T programs. For investors and investigators, the shift is a direct signal that CDH17 targeting remains a high-interest biology, but that the current autologous ex vivo manufacturing and dosing scheme will not continue as tested.